ACADIA Pharmaceuticals Inc. Accounts Receivable Turnover

Accounts Receivable Turnover of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Accounts Receivable Turnover growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Accounts Receivable Turnover for 2020 was 10.02 (a -2.96% decrease from previous year)
  • Annual Accounts Receivable Turnover for 2019 was 10.33 (a 6.64% increase from previous year)
  • Annual Accounts Receivable Turnover for 2018 was 9.68 (a -0.87% decrease from previous year)
  • Twelve month Accounts Receivable Turnover ending December 30, 2020 was 10.02 (a -4.28% decrease compared to previous quarter)
  • Twelve month trailing Accounts Receivable Turnover increased by 7.21% year-over-year
Trailing Accounts Receivable Turnover for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
10.02 10.47 9.97 9.35
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Accounts Receivable Turnover of ACADIA Pharmaceuticals Inc.

Most recent Accounts Receivable Turnoverof ACAD including historical data for past 10 years.

Interactive Chart of Accounts Receivable Turnover of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Accounts Receivable Turnover for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 10.02
2019 10.33
2018 9.68
2017 9.77
2016 3.95
2015 0.05
2014 0.14
2013 0.0
2012 0.0
2011 0.0
2010 0.0

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.